CRISPR/Cas-based ex-vivo autologous hematopoietic stem cell therapy (Aarhus University)

N/A

Report date: 2025/06/11 10:58:09

Base Information

Drug NameCRISPR/Cas-based ex-vivo autologous hematopoietic stem cell therapy (Aarhus University)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy
Mechanisms of ActionSignal transducer and activator of transcription 3 modulators
TargetsSignal transducer and activator of transcription 3
Therapy Area/IndicationsJob Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryDenmark
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAarhus University
China Registration ClassN/A

Develop Information

Active CompaniesAarhus University
Inactive CompaniesN/A
Active IndicationsJob Syndrome
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A